| Identification | Back Directory | [Name]
PB-22-d9 | [CAS]
2484977-00-4 | [Synonyms]
PB-22-d9
1-pentyl-2,2',3,3',4,4',5,5,5-d9-8-quinolinylester-1H-indole-3-carboxylicacid | [Molecular Formula]
C23H13D9N2O2 | [MOL File]
2484977-00-4.mol | [Molecular Weight]
367.488 |
| Hazard Information | Back Directory | [Description]
PB-22-d9 (exempt preparation) (Item No. 22871) is intended for use as an internal standard for the quantification of PB-22 (Item No. ISO00122) by GC- or LC-MS. PB-22 is categorized as a synthetic cannabinoid.1 It mimics the effects of Δ9-THC (Item Nos. 12068 | ISO60157). PB-22 is regulated as a Schedule I compound in the United States. PB-22-d9 (exempt preparation) (Item No. 22871) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use. | [Description]
PB-22-d9 (Item No. 14298) is intended for use as an internal standard for the quantification of PB-22 (Item No. ISO00122) by GC- or LC-MS. PB-22 is categorized as a synthetic cannabinoid.1 It mimics the effects of Δ9-THC (Item Nos. 12068 | ISO60157). PB-22-d9 is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use. | [References]
[1] SAMUEL D. BANISTER. Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135[J]. ACS Chemical Neuroscience, 2015, 6 8: 1445-1458. DOI: 10.1021/acschemneuro.5b00107 |
|
|